Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720

PURPOSE: Cancer and Leukemia Group B (CALGB) 9720 evaluated subcutaneous low-dose recombinant interleukin-2 (rIL-2) maintenance immunotherapy as a strategy for prolonging remission in older patients with acute myeloid leukemia (AML). PATIENTS AND METHODS: AML patients age 60 years and older in first...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Baer, Maria R., George, Stephen L., Caligiuri, Michael A., Sanford, Ben L., Bothun, Sandra M., Mrózek, Krzysztof, Kolitz, Jonathan E., Powell, Bayard L., Moore, Joseph O., Stone, Richard M., Anastasi, John, Bloomfield, Clara D., Larson, Richard A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2008
Assuntos:
Leukemia and Bone Marrow Transplantation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2652081/
https://ncbi.nlm.nih.gov/pubmed/18591543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.17.0472
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados